Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil

Keyphrases

• Infliximab 100%
• Sarcoidosis 100%
• Mycophenolate Mofetil 100%
• Neurosarcoidosis 33%
• CNS Involvement 33%
• Treatment Response 16%
• Neutralizing Antibodies 16%
• Neurological Examination 16%
• MRI Scan 16%
• Therapeutic Approaches 16%
• Symptomatic Improvement 16%
• Cord 16%
• Lesion Size 16%
• Anti-tumor Necrosis Factor (anti-TNF) 16%
• Biopsy-proven 16%
• Dural 16%
• Combination Treatment 16%
• Single Lesion 16%
• Treatment Failure 16%
• Intraparenchymal 16%
• Motor Coordination 16%
• Neuropathic Pain 16%
• Seizure Activity 16%
• Motor-sensory 16%
• Antiproliferative Activity 16%
• Leptomeningeal 16%
• Late Gadolinium Enhancement 16%
• Serious Adverse Effects 16%
• Headache Pain 16%
• Positive Treatment 16%
• Infliximab Therapy 16%

Neuroscience

• Sarcoidosis 100%
• Infliximab 100%
• Mycophenolate Mofetil 100%
• Magnetic Resonance Imaging 28%
• Adverse Effect 14%
• Headache 14%
• Immunosuppressant 14%
• Necrosis 14%
• Neuropathic Pain 14%
• Neutralizing Antibody 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Infliximab 100%
• Sarcoidosis 100%
• Mycophenolate Mofetil 100%
• Neurosarcoidosis 28%
• Tumor Necrosis Factor 14%
• Neutralizing Antibody 14%
• Headache 14%
• Immunosuppressive Agent 14%
• Neuropathic Pain 14%
• Gadolinium 14%